Introduction/Background To estimate the incidence of abdominal wall metastases (AWM) and their impact on overall survival in patients with advanced low-grade serous ovarian cancer (LGSOC).

Methodology Patients with advanced LGSOC (FIGO stage III–IV) undergoing primary and/or secondary cytoreductive surgery at our Institution between August 2001 and August 2016 were retrospectively identified. Incidence of AWM was evaluated by review of electronic medical records. Overall survival was estimated using the Kaplan-Meier method.

Results Total of 60 women who met inclusion criteria were identified. Of them, 30 (50%) patients had AWM, including 12 (20%) at primary surgery, 18 (30%) at relapse, or both 8 (13.3%). Among patients with evidence of AWM at primary surgery, 11 (91.7%) had prior surgery (10 laparoscopic, 1 laparotomy). Median follow-up was 87 (IQR 51, 127) years. Among the 60 patients, 24 (40%) died of disease [17/30 (56.7%) vs. 8/30 (26.7%) in the groups with and without AWM, respectively]. The median overall survival in the group of patients with AWM was lower than in the group without AWM (80 months; 95% CI 80–103 vs. 89 months; 95% CI 73–104, respectively, Log rank test, P=0.085), although not statistically significant.

Conclusion Incidence of AWM in advanced LGSOC is high (50% in the present series) compared to high-grade serous epithelial ovarian cancer (3–5%) (Cormio et al, 2003, Gynecologic Oncology) and is associated with decreased overall survival.

Disclosure Nothing to disclose.